{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:58:19Z","timestamp":1792486699090,"version":"4.5.0"},"reference-count":117,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"33","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,11,20]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Bone loss resulting from the treatment of breast and prostate cancer is an emerging problem. Bisphosphonates have a potential role in the prevention of this cancer treatment\u2013induced bone loss (CTIBL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Studies evaluating the incidence and prevalence of CTIBL in early breast and prostate cancer patients and trials evaluating the preventative role of bisphosphonates were identified by a search of the PubMed and Cochrane Library databases through the end of March 2008. Reference lists from retrieved articles were cross referenced, and further information was obtained from relevant scientific meetings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Several therapies commonly used in the treatment of women and men with breast and prostate cancers, in particular the aromatase inhibitors (AIs) for breast cancer and androgen deprivation therapy (ADT) for prostate cancer, are associated with significant bone loss and with an increase in fracture risk. The use of bisphosphonates seems to attenuate the bone loss, although the long-term impact remains unclear because of insufficient follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adjuvant endocrine therapy with an AI or androgen deprivation can be considered a risk factor for the development of osteopenia, osteoporosis, and bone fracture, which can be mitigated by appropriate bisphosphonate therapy. Clear identification of risk factors for osteoporosis in individual patients should aid treatment decisions about whether to use bisphosphonates when starting or switching to an AI or ADT. Patients need to be educated about this risk and other measures to avoid this complication, including lifestyle modifications that may benefit their general and bone health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2008.18.4184","type":"journal-article","created":{"date-parts":[[2008,10,27]],"date-time":"2008-10-27T20:14:37Z","timestamp":1225138477000},"page":"5465-5476","source":"Crossref","is-referenced-by-count":156,"title":["Cancer Treatment\u2013Induced Bone Loss in Breast and Prostate Cancer"],"prefix":"10.1200","volume":"26","author":[{"given":"Fred","family":"Saad","sequence":"first","affiliation":[{"name":"From the Department of Surgery\/Urology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, University of Montreal, Montreal; Department of Rheumatology, University of Laval, Sainte-Foy, Quebec; Department of Medicine, St. Joseph's Healthcare, McMaster University, Hamilton; Kaleidoscope Strategic Inc; Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario; British Columbia..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Adachi","sequence":"additional","affiliation":[{"name":"From the Department of Surgery\/Urology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, University of Montreal, Montreal; Department of Rheumatology, University of Laval, Sainte-Foy, Quebec; Department of Medicine, St. Joseph's Healthcare, McMaster University, Hamilton; Kaleidoscope Strategic Inc; Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario; British Columbia..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques P.","family":"Brown","sequence":"additional","affiliation":[{"name":"From the Department of Surgery\/Urology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, University of Montreal, Montreal; Department of Rheumatology, University of Laval, Sainte-Foy, Quebec; Department of Medicine, St. Joseph's Healthcare, McMaster University, Hamilton; Kaleidoscope Strategic Inc; Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario; British Columbia..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah A.","family":"Canning","sequence":"additional","affiliation":[{"name":"From the Department of Surgery\/Urology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, University of Montreal, Montreal; Department of Rheumatology, University of Laval, Sainte-Foy, Quebec; Department of Medicine, St. Joseph's Healthcare, McMaster University, Hamilton; Kaleidoscope Strategic Inc; Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario; British Columbia..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Gelmon","sequence":"additional","affiliation":[{"name":"From the Department of Surgery\/Urology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, University of Montreal, Montreal; Department of Rheumatology, University of Laval, Sainte-Foy, Quebec; Department of Medicine, St. Joseph's Healthcare, McMaster University, Hamilton; Kaleidoscope Strategic Inc; Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario; British Columbia..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Josse","sequence":"additional","affiliation":[{"name":"From the Department of Surgery\/Urology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, University of Montreal, Montreal; Department of Rheumatology, University of Laval, Sainte-Foy, Quebec; Department of Medicine, St. Joseph's Healthcare, McMaster University, Hamilton; Kaleidoscope Strategic Inc; Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario; British Columbia..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen I.","family":"Pritchard","sequence":"additional","affiliation":[{"name":"From the Department of Surgery\/Urology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, University of Montreal, Montreal; Department of Rheumatology, University of Laval, Sainte-Foy, Quebec; Department of Medicine, St. Joseph's Healthcare, McMaster University, Hamilton; Kaleidoscope Strategic Inc; Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario; British Columbia..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0210"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050304"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1780-5"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0343-y"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Chaiamnuay S, Saag KG: Postmenopausal osteoporosis: What have we learned since the introduction of bisphosphonates? Rev Endocr Metab Disord 7:101,2006-112,","DOI":"10.1007\/s11154-006-9008-y"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90002-1"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh141"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11701"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20308"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020299707510"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.78"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Cosman F, Lindsay R: Selective estrogen receptor modulators: Clinical spectrum. Endocr Rev 20:418,1999-434,","DOI":"10.1210\/edrv.20.3.0371"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0015"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.121"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2006.n.021"},{"key":"R18","unstructured":"Carney JF, Davis J: Emerging bone health issues in women with breast cancer in Hawai\u2019i. Hawaii Med J 66:164,2007-166,"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17666-6"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67059-6"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8054"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.120"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60200-1"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji250"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8617"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060508"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.06.004"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70003-7"},{"key":"R29","unstructured":"Asmar L, Negron A, Stokoe C, et al: The effect of tamoxifen or exemestane on bone mineral density after 2 years of adjuvant treatment of postmenopausal women with early breast cancer. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17 , 2006 (abstr 2102)"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.07.005"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2006.06.027"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4882"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70385-6"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Coleman RE, Group AT: Effect of anastrozole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24:5s,2006,  (suppl; abstr 511)","DOI":"10.1200\/jco.2006.24.18_suppl.511"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2003.11.006"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0438"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-3803-0"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.3694"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1508-y"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3306"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.3109\/07357909809039747"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.58"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-005-0798-3"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(03)00127-X"},{"key":"R45","unstructured":"De Boer R, Eidtmann H, Lluch A, et al: The ZO-FAST trial: Zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. Breast Cancer Res Treat 106:501,2007,  (suppl 1)"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Brufsky A, Bosserman L, Caradonna R, et al: The effect of zoledronic acid on aromatase-inhibitor-associated bone loss in postmenopausal women with early breast cancer reciving adjuvant letrozole: The Z-FAST study 36-month follow-up. Breast Cancer Res Treat 106:27,2007,  (suppl 1)","DOI":"10.1016\/S1359-6349(08)70810-3"},{"key":"R47","unstructured":"Van Poznak C, Hannon R, Clack G, et al: The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. Breast Cancer Res Treat 106:502,2007,  (suppl 1)"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.8312"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.9.704"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.5325"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1272"},{"key":"R53","unstructured":"Hershman D, McMahon D, Crew K, et al: Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early stage breast cancer. Breast Cancer Res Treat 106:506,2007,  (abstr)"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.955"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.1023\/B:BREA.0000041624.00665.4e"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1444"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00317-3"},{"key":"R58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1341"},{"key":"R59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7102"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3744"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23259"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.2.238"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.1559"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04471.x"},{"key":"R66","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119701"},{"key":"R67","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.11.1833"},{"key":"R68","doi-asserted-by":"crossref","unstructured":"Khosla S, Melton LJ 3rd, Atkinson EJ, et al: Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266,1998-2274,","DOI":"10.1210\/jc.83.7.2266"},{"key":"R69","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00999-7"},{"key":"R70","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0183"},{"key":"R71","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000127738.94221.da"},{"key":"R72","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.2546"},{"key":"R73","doi-asserted-by":"publisher","DOI":"10.1080\/00365590310018810"},{"key":"R74","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.07.019"},{"key":"R75","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.03.012"},{"key":"R76","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500599"},{"key":"R77","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64985-3"},{"key":"R78","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.8.8782"},{"key":"R79","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68000-7"},{"key":"R80","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61639-2"},{"key":"R81","doi-asserted-by":"publisher","DOI":"10.1007\/BF00298427"},{"key":"R82","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07163.x"},{"key":"R83","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.05.135"},{"key":"R84","unstructured":"Malcolm JB, Derweesh IH, Kincade MC, et al: Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 14:3551,2007-3559,"},{"key":"R85","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00033-9"},{"key":"R86","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H209"},{"key":"R87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041943"},{"key":"R88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.6908"},{"key":"R89","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1799-7"},{"key":"R90","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20388"},{"key":"R91","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000143930.73016.c6"},{"key":"R92","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000130508.61020.66"},{"key":"R93","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000059281.67667.97"},{"key":"R94","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65661-3"},{"key":"R95","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2000.00774.x"},{"key":"R96","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3"},{"key":"R97","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65165-6"},{"key":"R98","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2007.n.003"},{"key":"R99","doi-asserted-by":"crossref","unstructured":"Casey R: Zoledronic acid reduces bone loss in men with prostate cancer receiving goserelin: 12-month results. Presented at the American Society of Clinical Oncology Prostate Cancer Symposium , Orlando, FL, February 22-24, 2007","DOI":"10.1016\/S1569-9056(07)60712-X"},{"key":"R100","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-6-200703200-00006"},{"key":"R101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3361"},{"key":"R102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06853.x"},{"key":"R103","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.04.078"},{"key":"R104","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.01.012"},{"key":"R105","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040813"},{"key":"R106","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000063820.94994.95"},{"key":"R107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010845"},{"key":"R108","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M"},{"key":"R109","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.11.002"},{"key":"R110","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00379-8"},{"key":"R111","doi-asserted-by":"crossref","unstructured":"Stoch SA, Parker RA, Chen L, et al: Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86:2787,2001-2791,","DOI":"10.1210\/jc.86.6.2787"},{"key":"R112","doi-asserted-by":"crossref","unstructured":"Kiratli BJ, Srinivas S, Perkash I, et al: Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57:127,2001-132,","DOI":"10.1016\/S0090-4295(00)00895-5"},{"key":"R113","doi-asserted-by":"crossref","unstructured":"Ryan CW, Huo D, Stallings JW, et al: Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70:122,2007-126,","DOI":"10.1016\/j.urology.2007.03.026"},{"key":"R114","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00301-5"},{"key":"R115","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64561-2"},{"key":"R116","doi-asserted-by":"crossref","unstructured":"Tyrrell CJ, Blake GM, Iversen P, et al: The non-steroidal antiandrogen, bicalutamide (Casodex), may preserve bone mineral density as compared with castration: Results of a preliminary study. World J Urol 21:37,2003-42,","DOI":"10.1007\/s00345-003-0322-7"},{"key":"R117","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0707onj"},{"key":"R118","unstructured":"Brown JP, Josse RG: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:S1,2002-S34,  (suppl)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.18.4184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:21:24Z","timestamp":1653510084000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.18.4184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,20]]},"references-count":117,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2008,11,20]]}},"alternative-id":["10.1200\/JCO.2008.18.4184"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.18.4184","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718357920.793494153","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,20]]}}}